Literature DB >> 3083462

L-dopa reverses the effects of MPP+ toxicity.

G C Wagner, M F Jarvis, J G Rubin.   

Abstract

The behavioral and neurochemical consequences of the intrastriatal administration of 1-methyl-4-phenylpyridinium ion (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were evaluated using the shuttlebox avoidance paradigm. MPP+ caused a significant depletion of striatal dopamine and significant disruption of shuttlebox performance. L-Dopa administration reversed both the dopamine depletion and the behavioral deficits. These observations are discussed in reference to the rodent-MPTP model of Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3083462     DOI： 10.1007/bf00180846

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  6 in total

1.  TEMPORARY AND PARTIAL ANTAGONISM BY L-DOPA OF RESERPINE-INDUCED SUPPRESSION OF A CONDITIONED AVOIDANCE RESPONSE.

Authors:  L S SEIDEN; A CARLSSON
Journal:  Psychopharmacologia       Date:  1963-08-20

2.  Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects.

Authors:  J N Johannessen; C C Chiueh; R S Burns; S P Markey
Journal:  Life Sci       Date:  1985-01-21       Impact factor: 5.037

3.  Tolerance following the repeated administration of high doses of phencyclidine: no relation to central catecholamine depletion.

Authors:  G C Wagner; J Gardner; D J Tsigas; D B Masters
Journal:  Drug Alcohol Depend       Date:  1984-05       Impact factor: 4.492

4.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

5.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R S Burns; C C Chiueh; S P Markey; M H Ebert; D M Jacobowitz; I J Kopin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

6.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.

Authors:  R E Heikkila; L Manzino; F S Cabbat; R C Duvoisin
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962
  6 in total
  1 in total

1.  Increased sensitivity of mice to tremorogenic agents following MPP+.

Authors:  G C Wagner; S L Walsh
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.